Brokerages Anticipate Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Will Post Earnings of -$0.15 Per Share

Equities research analysts expect Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to announce earnings per share (EPS) of ($0.15) for the current quarter, Zacks reports. Zero analysts have made estimates for Cyclacel Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.14). Cyclacel Pharmaceuticals posted earnings per share of ($0.16) during the same quarter last year, which suggests a positive year over year growth rate of 6.3%. The business is scheduled to announce its next earnings results on Thursday, August 8th.

On average, analysts expect that Cyclacel Pharmaceuticals will report full-year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.57). For the next year, analysts anticipate that the business will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.59) to ($0.58). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04.

Several brokerages have recently issued reports on CYCC. Roth Capital reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a report on Thursday, May 23rd. Zacks Investment Research raised shares of Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating and set a $0.75 price target for the company in a report on Friday, May 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a report on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Cyclacel Pharmaceuticals has an average rating of “Buy” and an average target price of $5.50.

Shares of CYCC stock remained flat at $$0.54 on Monday. 130,625 shares of the stock traded hands, compared to its average volume of 139,090. Cyclacel Pharmaceuticals has a one year low of $0.51 and a one year high of $1.87. The company has a quick ratio of 8.09, a current ratio of 8.09 and a debt-to-equity ratio of 0.08. The business’s fifty day simple moving average is $0.62.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

Recommended Story: What are gap-down stocks?

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.